MX379424B - Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. - Google Patents
Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis.Info
- Publication number
- MX379424B MX379424B MX2015011878A MX2015011878A MX379424B MX 379424 B MX379424 B MX 379424B MX 2015011878 A MX2015011878 A MX 2015011878A MX 2015011878 A MX2015011878 A MX 2015011878A MX 379424 B MX379424 B MX 379424B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- fibrosis
- alkenyl
- alkyl
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798269P | 2013-03-15 | 2013-03-15 | |
| PCT/CA2014/000236 WO2014138906A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds and related method for the treatment of fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011878A MX2015011878A (es) | 2016-06-07 |
| MX379424B true MX379424B (es) | 2025-03-11 |
Family
ID=51535669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011878A MX379424B (es) | 2013-03-15 | 2014-03-14 | Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10023518B2 (enExample) |
| EP (1) | EP2970089B1 (enExample) |
| JP (1) | JP6448562B2 (enExample) |
| KR (1) | KR102196721B1 (enExample) |
| CN (2) | CN105189438A (enExample) |
| AR (1) | AR095429A1 (enExample) |
| AU (1) | AU2014231648B2 (enExample) |
| BR (1) | BR112015022008A2 (enExample) |
| CA (1) | CA2905621C (enExample) |
| CL (1) | CL2015002535A1 (enExample) |
| DK (1) | DK2970089T3 (enExample) |
| EA (1) | EA030651B1 (enExample) |
| ES (1) | ES2741439T3 (enExample) |
| IL (1) | IL241178B (enExample) |
| MX (1) | MX379424B (enExample) |
| MY (1) | MY180305A (enExample) |
| NZ (1) | NZ712797A (enExample) |
| PH (1) | PH12015502011B1 (enExample) |
| PL (1) | PL2970089T3 (enExample) |
| PT (1) | PT2970089T (enExample) |
| SG (1) | SG11201507408XA (enExample) |
| TW (1) | TWI689490B (enExample) |
| UY (1) | UY35402A (enExample) |
| WO (1) | WO2014138906A1 (enExample) |
| ZA (1) | ZA201507061B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| HUE050215T2 (hu) | 2013-01-15 | 2020-11-30 | Incyte Holdings Corp | Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| RU2709205C2 (ru) * | 2014-10-10 | 2019-12-17 | Прометик Фарма Смт Лимитед | Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза |
| SG11201702812PA (en) * | 2014-10-10 | 2017-05-30 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
| US10391073B2 (en) * | 2014-11-12 | 2019-08-27 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
| SG11201707555RA (en) * | 2015-03-18 | 2017-10-30 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20190144547A1 (en) * | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| TWI650125B (zh) * | 2016-05-19 | 2019-02-11 | 長弘生物科技股份有限公司 | 用於延緩肺纖維化之發病及／或治療肺纖維化之藥劑 |
| TWI750189B (zh) | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| KR102126389B1 (ko) * | 2018-09-14 | 2020-06-25 | 셀라이온바이오메드 주식회사 | 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물 |
| CA3112073A1 (en) | 2018-10-11 | 2020-04-16 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| US20240043372A1 (en) * | 2020-10-06 | 2024-02-08 | Pharmaceutique Ingenew Inc. | Substituted aromatic compounds and pharmaceutical compositions thereof |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183519A1 (en) * | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| JP2009538359A (ja) * | 2006-05-26 | 2009-11-05 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換カルボン酸化合物の製造および利用 |
| WO2008112368A2 (en) * | 2007-02-08 | 2008-09-18 | Emisphere Technologies, Inc. | Phenylalkylcarboxylic acid delivery agents |
| TWI485134B (zh) * | 2009-05-04 | 2015-05-21 | 波麥堤克生化科學公司 | 取代的芳族化合物及其藥學用途 |
| JP5844251B2 (ja) * | 2009-05-04 | 2016-01-13 | プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． | ３−ペンチルフェニル酢酸の塩およびその薬学的使用 |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
-
2014
- 2014-03-12 TW TW103108723A patent/TWI689490B/zh not_active IP Right Cessation
- 2014-03-13 AR ARP140100973A patent/AR095429A1/es unknown
- 2014-03-13 UY UY0001035402A patent/UY35402A/es not_active Application Discontinuation
- 2014-03-14 CN CN201480013578.9A patent/CN105189438A/zh active Pending
- 2014-03-14 BR BR112015022008-8A patent/BR112015022008A2/pt active Search and Examination
- 2014-03-14 PL PL14764458T patent/PL2970089T3/pl unknown
- 2014-03-14 AU AU2014231648A patent/AU2014231648B2/en not_active Ceased
- 2014-03-14 MX MX2015011878A patent/MX379424B/es unknown
- 2014-03-14 WO PCT/CA2014/000236 patent/WO2014138906A1/en not_active Ceased
- 2014-03-14 NZ NZ712797A patent/NZ712797A/en not_active IP Right Cessation
- 2014-03-14 CA CA2905621A patent/CA2905621C/en active Active
- 2014-03-14 CN CN201910355464.7A patent/CN110105200B/zh not_active Expired - Fee Related
- 2014-03-14 ES ES14764458T patent/ES2741439T3/es active Active
- 2014-03-14 US US14/776,328 patent/US10023518B2/en active Active
- 2014-03-14 EP EP14764458.7A patent/EP2970089B1/en active Active
- 2014-03-14 EA EA201591775A patent/EA030651B1/ru not_active IP Right Cessation
- 2014-03-14 JP JP2015561849A patent/JP6448562B2/ja not_active Expired - Fee Related
- 2014-03-14 PT PT14764458T patent/PT2970089T/pt unknown
- 2014-03-14 MY MYPI2015002293A patent/MY180305A/en unknown
- 2014-03-14 DK DK14764458.7T patent/DK2970089T3/da active
- 2014-03-14 SG SG11201507408XA patent/SG11201507408XA/en unknown
- 2014-03-14 KR KR1020157029293A patent/KR102196721B1/ko not_active Expired - Fee Related
-
2015
- 2015-09-03 IL IL241178A patent/IL241178B/en active IP Right Grant
- 2015-09-09 PH PH12015502011A patent/PH12015502011B1/en unknown
- 2015-09-09 CL CL2015002535A patent/CL2015002535A1/es unknown
- 2015-09-22 ZA ZA2015/07061A patent/ZA201507061B/en unknown
-
2018
- 2018-04-04 US US15/945,408 patent/US10550066B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 US US16/780,316 patent/US11524930B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379424B (es) | Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. | |
| MX375261B (es) | Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| WO2012174487A3 (en) | Bromodomain inhibitors and uses thereof | |
| WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| WO2014099633A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| WO2012071369A3 (en) | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease | |
| MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
| FR2977486B1 (fr) | Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique | |
| HK1219222A1 (zh) | 包含降血脂药的制剂 | |
| HK1218537A1 (zh) | 香豆素衍生物以及用於治疗过度增生性疾病的方法 | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| WO2012131656A3 (en) | Compounds for use as therapeutic agents affecting p53 expression and/or activity | |
| WO2014130752A3 (en) | Bicyclic compounds | |
| PH12019500822B1 (en) | Crystalline forms of eravacycline | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. |